These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 15748093)

  • 1. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2005; 23(2):193-206. PubMed ID: 15748093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.
    Jones RW; McCrone P; Guilhaume C
    Drugs Aging; 2004; 21(9):607-20. PubMed ID: 15260515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease : a markov model in Finland.
    François C; Sintonen H; Sulkava R; Rive B
    Clin Drug Investig; 2004; 24(7):373-84. PubMed ID: 17516724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.
    Wimo A; Winblad B; Stöffler A; Wirth Y; Möbius HJ
    Pharmacoeconomics; 2003; 21(5):327-40. PubMed ID: 12627986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
    Antonanzas F; Rive B; Badenas JM; Gomez-Lus S; Guilhaume C
    Eur J Health Econ; 2006 Jun; 7(2):137-44. PubMed ID: 16670912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
    Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A
    Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine: a review of its use in Alzheimer's disease.
    Robinson DM; Keating GM
    Drugs; 2006; 66(11):1515-34. PubMed ID: 16906789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.
    Weycker D; Taneja C; Edelsberg J; Erder MH; Schmitt FA; Setyawan J; Oster G
    Curr Med Res Opin; 2007 May; 23(5):1187-97. PubMed ID: 17519086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2002; 20(13):919-42. PubMed ID: 12381243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of memantine for the treatment of Alzheimer's disease.
    Ferris SH
    Expert Opin Pharmacother; 2003 Dec; 4(12):2305-13. PubMed ID: 14640929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway.
    Rive B; Aarsland D; Grishchenko M; Cochran J; Lamure M; Toumi M
    Int J Geriatr Psychiatry; 2012 Jun; 27(6):573-82. PubMed ID: 21834130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of memantine in Alzheimer's disease in the UK.
    Rive B; Grishchenko M; Guilhaume-Goulant C; Katona C; Livingston G; Lamure M; Toumi M; François C
    J Med Econ; 2010; 13(2):371-80. PubMed ID: 20504112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.
    Cappell J; Herrmann N; Cornish S; Lanctôt KL
    CNS Drugs; 2010 Nov; 24(11):909-27. PubMed ID: 20932064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
    Pfeil AM; Kressig RW; Szucs TD
    Swiss Med Wkly; 2012; 142():w13676. PubMed ID: 23180021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
    Lamb HM; Goa KL
    Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on memantine in moderate to severe Alzheimer's disease.
    McKeage K
    Drugs Aging; 2010 Feb; 27(2):177-9. PubMed ID: 20104942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.